Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy

Journal of Clinical Oncology

Volumn 32, Issue 14, 2014, Pages

  Harding, James J ^a   Barker, Christopher A ^a   Carvajal, Richard D ^a   Wolchok, Jedd D ^a   Chapman, Paul B ^a   Lacouture, Mario E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCLOMETASONE; ANTIBIOTIC AGENT; B RAF KINASE; EMOLLIENT AGENT; RETINOID; SALICYLIC ACID; VEMURAFENIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; SULFONAMIDE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER RADIOTHERAPY; CANCER SIZE; CASE REPORT; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CUTIS VERTICIS GYRATA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG ERUPTION; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; HUMAN TISSUE; MALE; METASTATIC MELANOMA; MIDDLE AGED; ORBIT METASTASIS; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; RECURRENCE RISK; SKIN DISEASE; TOPICAL TREATMENT; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TUMOR BIOPSY; MELANOMA; METASTASIS; PATHOLOGY; SKIN TUMOR; SKULL IRRADIATION;

ADULT; ANTINEOPLASTIC AGENTS; CRANIAL IRRADIATION; FEMALE; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SCALP DERMATOSES; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84902797015     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.3528     Document Type: Article

References (18)

1. Schons KR, Beber AA: Images in clinical medicine: Cutis verticis gyrata. N Engl J Med 367:e23, 2012
2. Walia R, Bhansali A: Cutis verticis gyrata. BMJ Case Rep doi: 10.1136/bcr.01.2011.3763 [epub ahead of print on June 3, 2011]
3. Cheson BD, Christiansen RM: Cutis verticis gyrata: Unusual chloromatous disease in acute myelogenous leukemia. Am J Hematol 8:415-418, 1980 (Pubitemid 10090043)
4. Kim JE, Choi KH, Kang SJ, et al: Angiosarcoma mimicking cutis verticis gyrata. Clin Exp Dermatol 36:806-808, 2011
5. Lacouture ME, Duvic M, Hauschild A, et al: Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 18:314-322, 2013
6. Callahan MK, Rampal R, Harding JJ, et al: Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 367:2316-2321, 2012
7. Hatzivassiliou G, Song K, Yen I, et al: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464:431-435, 2010
8. Poulikakos PI, Zhang C, Bollag G, et al: RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427-430, 2010
9. Su F, Viros A, Milagre C, et al: RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207-215, 2012
10. Sitton E: Early and late radiation-induced skin alterations: Part I. Mechanisms of skin changes. Oncol Nurs Forum 19:801-807, 1992
11. Bentzen SM: Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology. Nat Rev Cancer 6:702-713, 2006
12. Sambade MJ, Peters EC, Thomas NE, et al: Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 98:394-399, 2011
13. Dasgupta T, Haas-Kogan DA, Yang X, et al: Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas. Invest New Drugs [epub ahead of print on January 26, 2013]
14. Dent P, Yacoub A, Fisher PB, et al: MAPK pathways in radiation responses. Oncogene 22:5885-5896, 2003 (Pubitemid 37176709)
15. Rochet NM, Dronca RS, Kottschade LA, et al: Melanoma brain metastases and vemurafenib: Need for further investigation. Mayo Clin Proc 87:976-981, 2012
16. Lee JM, Mehta UN, Dsouza LH, et al: Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: A case report. Melanoma Res 23:175-178, 2013
17. Long GV, Trefzer U, Davies MA, et al: Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAKMB): A multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087-1095, 2012
18. Wang CM, Fleming KF, Hsu S: A case of vemurafenib-induced keratosis pilaris-like eruption. Dermatol Online J 18:7, 2012